GLMD — Galmed Pharmaceuticals Cashflow Statement
0.000.00%
- $3.61m
- -$12.12m
- 23
- 57
- 31
- 30
Annual cashflow statement for Galmed Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -28.8 | -32.5 | -17.9 | -6.91 | -7.52 |
Depreciation | |||||
Non-Cash Items | 1.34 | 1.98 | 1.78 | 0.612 | 2.28 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.1 | -2.45 | -2.45 | 0.132 | -0.728 |
Change in Accounts Receivable | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -26.3 | -32.9 | -18.5 | -6.14 | -5.88 |
Capital Expenditures | -0.044 | -0.011 | -0.004 | 0 | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 16.6 | 11.5 | 17.6 | 0.8 | -1.11 |
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 16.5 | 11.5 | 17.6 | 0.8 | -1.11 |
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 0.768 | 17.4 | 0.07 | 6.18 | 8.79 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -8.98 | -4.06 | -0.868 | 0.848 | 1.79 |